Literature DB >> 10027940

Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus.

F Wollesen1, L Brattström, H Refsum, P M Ueland, L Berglund, C Berne.   

Abstract

BACKGROUND: The plasma concentrations of total homocysteine (tHcy) and total cysteine (tCys) are determined by intracellular metabolism and by renal plasma clearance, and we hypothesized that glomerular filtration is a major determinant of plasma tHcy and tCys. We studied the relationships between the glomerular filtration rate (GFR) and plasma tHcy and tCys in populations of diabetic patients with particularly wide ranges of GFR.
METHODS: We measured GFR, urine albumin excretion rate (UAER), plasma tHcy, tCys, methionine, vitamin B12, folate, C-peptide, and routine parameters in 50 insulin-dependent diabetes mellitus (IDDM) and 30 non-insulin-dependent diabetes mellitus (NIDDM) patients. All patients underwent intensive insulin treatment and had a serum creatinine concentration below 115 micromol/liter.
RESULTS: Mean plasma tHcy in diabetic patients (0.1 micromol/liter) was lower than in normal persons (11.1 micromol/liter, P = 0.0014). Mean plasma tCys in diabetic patients (266.1 micromol/liter) was also lower than in normal persons (281.9 micromol/liter, P = 0.0005). Seventy-three percent of the diabetic patients had relative hyperfiltration. Plasma tHcy and tCys were closely and independently associated with GFR, serum folate, and serum B12. However, plasma tHcy was not independently associated with any of the 22 other variables tested, including age, serum creatinine concentration, UAER, total daily insulin dose, and glycemic control.
CONCLUSIONS: Glomerular filtration rate is an independent determinant of plasma tHcy and tCys concentrations, and GFR is rate limiting for renal clearance of both homocysteine and cysteine in diabetic patients without overt nephropathy. Declining GFR explains the age-related increase in plasma tHcy, and hyperfiltration explains the lower than normal mean plasma tHcy and tCys concentrations in populations of diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027940     DOI: 10.1046/j.1523-1755.1999.0550031028.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  47 in total

1.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: a prospective study.

Authors:  Arpita Basu; Alicia J Jenkins; Julie A Stoner; Suzanne R Thorpe; Richard L Klein; Maria F Lopes-Virella; W Timothy Garvey; Timothy J Lyons
Journal:  Atherosclerosis       Date:  2014-07-15       Impact factor: 5.162

3.  Cystathionine beta synthase gene dose dependent vascular remodeling in murine model of hyperhomocysteinemia.

Authors:  Neetu Tyagi; Natia Qipshidze; Utpal Sen; Walter Rodriguez; Alexander Ovechkin; Suresh C Tyagi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-08

4.  Folic acid, vitamin B12, and homocysteine levels during fasting and after methionine load in patients with Type 1 diabetes mellitus.

Authors:  A Giannattasio; M G Calevo; G Minniti; D Gianotti; M Cotellessa; F Napoli; R Lorini; G d'Annunzio
Journal:  J Endocrinol Invest       Date:  2010-10-15       Impact factor: 4.256

5.  A prospective controlled study of kidney donors: baseline and 6-month follow-up.

Authors:  Bertram L Kasiske; Teresa Anderson-Haag; Hassan N Ibrahim; Todd E Pesavento; Matthew R Weir; Joseph M Nogueira; Fernando G Cosio; Edward S Kraus; Hamid H Rabb; Roberto S Kalil; Andrew A Posselt; Paul L Kimmel; Michael W Steffes
Journal:  Am J Kidney Dis       Date:  2013-03-22       Impact factor: 8.860

6.  Homocysteine as a risk factor for development of microalbuminuria in type 2 diabetes.

Authors:  Eun-Hee Cho; Eun Hee Kim; Won Gu Kim; Eun Hui Jeong; Eun Hee Koh; Woo-Je Lee; Min-Seon Kim; Joong-Yeol Park; Ki-Up Lee
Journal:  Korean Diabetes J       Date:  2010-06-30

7.  Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?

Authors:  Utpal Sen; Suresh C Tyagi
Journal:  PPAR Res       Date:  2010-06-29       Impact factor: 4.964

8.  Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.

Authors:  Karsten Suhre; Christa Meisinger; Angela Döring; Elisabeth Altmaier; Petra Belcredi; Christian Gieger; David Chang; Michael V Milburn; Walter E Gall; Klaus M Weinberger; Hans-Werner Mewes; Martin Hrabé de Angelis; H-Erich Wichmann; Florian Kronenberg; Jerzy Adamski; Thomas Illig
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

Review 9.  Homocysteine in renovascular complications: hydrogen sulfide is a modulator and plausible anaerobic ATP generator.

Authors:  Utpal Sen; Sathnur B Pushpakumar; Matthew A Amin; Suresh C Tyagi
Journal:  Nitric Oxide       Date:  2014-06-22       Impact factor: 4.427

10.  Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.

Authors:  Utpal Sen; Walter E Rodriguez; Neetu Tyagi; Munish Kumar; Soumi Kundu; Suresh C Tyagi
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-09       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.